International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 6 November-December 2024 Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 6
November-December 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Direct Compression Development of Celecoxib Tablet through Solid State in Dimethyl Sulfoxide

Author(s) Deovrat kumar, Shalini Sharma, Aryavrat
Country India
Abstract Tablets are the most desirable solid oral dosage form for patients. Direct compression (DC) tablet formulation is the most economical, robust and efficient way of tablet manufacture. Being sensitive to properties of the Active Pharmaceutical Ingredient (API), direct compression tablet formulation is not available for the high dose non-steroidal anti-inflammatory drug, celecoxib (CEL) due to the undesirable properties of the commercial solid form of celecoxib, including low bulk density, poor flowability and tablet lamination issues.
The solid form used in commercially available celecoxib capsules is a polymorph of celecoxib, Form III. Form III celecoxib is a needle shaped crystal, which is exceptionally elastic. This high elasticity, verified by nano indentation and three-point bending tests, is unfavorable for good tablet quality and performance during high speed tableting. Through understanding the molecular interactions by analyzing the celecoxib crystal structure, a structural model for high elasticity is built and validated by Raman spectroscopy. Interlocked molecular packing without slip plane and the presence of isotropic hydrogen bond network are major structural features responsible for both the exceptional elastic flexibility and high stiffness of the celecoxib crystal.
celecoxib Form III exhibits unsatisfactory flowability and tablet lamination issues for DC tablet manufacturing. Pharmaceutically acceptable solvates of celecoxib offer better flow, compaction and dissolution properties than celecoxib Form III. Two stoichiometric solvates of celecoxib and N-methyl-2-pyrrolidone (NMP) are extensively characterized and examined, which establishes a clear crystal structure-property relationship essential for crystal vi

engineering of celecoxib. Through crystal engineering, a DC tablet formulation of celecoxib is successfully developed using the dimethyl sulfoxide (DMSO) solvate of celecoxib. This pharmaceutically acceptable solvate is highly stable and also exhibited much improved manufacturability compared to celecoxib Form III, including better flowability, lower elasticity and bulk density (superior tablet quality) as well as better dissolution performance.
As a Class II drug in the biopharmaceutics classification system with low solubility and high permeability, the high dose of celecoxib is partially attributed to its limited solubility. Amorphous celecoxib, although providing solubility advantages as the thermodynamically high energy state, is unstable and prone to crystallization. The study of crystal growth of amorphous celecoxib reveals a fast glass-to-crystal growth mode at room temperature with a surface-enhanced mechanism. This paves the way for future development of a stable amorphous solid dispersion tablet product of celecoxib with improved dissolution performance and tablet manufacturability.
In summary, by understanding the structural origin of undesired properties of celecoxib, successful development of the most patient-compliant tablet dosage form by direct compression can be achieved. This sets an excellent example of utilizing a solid state engineering approach to effectively overcome challenges encountered in direct compression tablet development.

Key words: CEL – Celecoxib, API (Active Pharmaceutical Limited),Raman Spectroscopy dimethyl sulfoxide (DMSO),etc
Keywords Key words: CEL – Celecoxib, API (Active Pharmaceutical Limited),Raman Spectroscopy dimethyl sulfoxide (DMSO),etc
Field Medical / Pharmacy
Published In Volume 6, Issue 6, November-December 2024
Published On 2024-11-22
Cite This Direct Compression Development of Celecoxib Tablet through Solid State in Dimethyl Sulfoxide - Deovrat kumar, Shalini Sharma, Aryavrat - IJFMR Volume 6, Issue 6, November-December 2024. DOI 10.36948/ijfmr.2024.v06i06.29690
DOI https://doi.org/10.36948/ijfmr.2024.v06i06.29690
Short DOI https://doi.org/
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 6Cover Page Vol 6 Isu 5Cover Page Vol 6 Isu 4

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com